List of works - Peter Meldgaard

18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods

scientific article published on 10 May 2017

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

scientific article published on 25 March 2014

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations.

scientific article published on 24 July 2018

A new quantitative RT-PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls

scientific article published on 01 January 2000

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project

scientific article published on 15 March 2019

Assessment of very early response evaluation with 18F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods.

scientific article published on 5 February 2018

Blood group ABO-related glycosylation of urothelial cell lines: immunocytological, enzymatic, and genetic characterization.

scientific article published on May 1994

Characterization of pulmonary lesions in patients with suspected lung cancer: computed tomography versus [¹⁸F] fluorodeoxyglucose-positron emission tomography/computed tomography.

scientific article

Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.

scientific article

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib

scientific article published on 01 November 2011

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients

scientific article published on 6 July 2017

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy.

scientific article published on 15 December 2015

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.

scientific article

Down-regulation of S100C is associated with bladder cancer progression and poor survival.

scientific article published on January 2005

EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib

scientific article

EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib

scientific article published on 26 February 2019

EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.

scientific article

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients

scientific article

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

scientific article published in July 2011

Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer.

scientific article published on 22 June 2016

Exosomal proteins as prognostic biomarkers in non-small cell lung cancer

scientific article published on 21 October 2016

Frailty status but not age predicts complications in elderly cancer patients: a follow-up study

scientific article published on 03 October 2018

Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations

scientific article published on August 2016

Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.

scientific article published on 8 September 2015

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients

scientific article published on 11 April 2020

Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer

scientific article published on 01 June 2004

Impact of comprehensive geriatric assessment on short-term mortality in older patients with cancer-a follow-up study

scientific article published on 01 June 2019

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib

scientific article published on 6 August 2016

Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.

scientific article published on 21 February 2015

Limited value of99mTc depreotide single photon emission CT compared with CT for the evaluation of pulmonary lesions ⬇️

scientific article published on July 1, 2012

Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer

scientific article published in August 2004

Loss of ABH antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus

scientific article published on 01 November 1995

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

scientific article published on 18 December 2014

Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.

scientific article published on 3 June 2014

Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib

scientific article

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

scientific article

PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

scientific article published on February 2016

PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer.

scientific article published on 17 November 2011

Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

scientific article published on 23 November 2017

Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples

scientific article published on 24 April 2017

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thora

scientific article

Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Le(b)/Le(a) glycosphingolipid, a novel extended type 1 chain antigen

scientific article published on 01 July 1992

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.

scientific article published on 15 February 2018

The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines

scientific article published on 01 March 1996

The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial

scientific article published on 25 November 2015

The prognostic role of inflammation-scores on overall survival in lung cancer patients

scientific article published on 11 January 2019

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

scientific article published on June 2006

Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers.

scientific article

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC

scientific article published on 16 December 2018

cGAS-STING pathway expression as a prognostic tool in NSCLC

scientific article published on 01 January 2021

List of works by Peter Meldgaard

18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations.

A new quantitative RT-PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project

Assessment of very early response evaluation with 18F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods.

Blood group ABO-related glycosylation of urothelial cell lines: immunocytological, enzymatic, and genetic characterization.

Characterization of pulmonary lesions in patients with suspected lung cancer: computed tomography versus [¹⁸F] fluorodeoxyglucose-positron emission tomography/computed tomography.

Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy.

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.

Down-regulation of S100C is associated with bladder cancer progression and poor survival.

EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib

EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib

EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer.

Exosomal proteins as prognostic biomarkers in non-small cell lung cancer

Frailty status but not age predicts complications in elderly cancer patients: a follow-up study

Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations

Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients

Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer

Impact of comprehensive geriatric assessment on short-term mortality in older patients with cancer-a follow-up study

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib

Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.

Limited value of99mTc depreotide single photon emission CT compared with CT for the evaluation of pulmonary lesions ⬇️

Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer

Loss of ABH antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.

Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer.

Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thora

Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Le(b)/Le(a) glycosphingolipid, a novel extended type 1 chain antigen

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.

The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines

The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial

The prognostic role of inflammation-scores on overall survival in lung cancer patients

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers.

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC

cGAS-STING pathway expression as a prognostic tool in NSCLC